Patent US3234322A successfully refreshed from Google Patents.
Patent US4281120A successfully refreshed from Google Patents.
US4281120A
Expired / Lapsed
US
⏱️ 0.0 years remaining
7H-1,3,4-Thiadiazolo-[3,2-a]-pyrimidin-7-one-5-carboxylic compounds
Assignee: Grünenthal GmbH
•
Filing: 1978-12-12
•
Granted: 1981-07-28
•
Expires: 1998-12-12
Abstract
Abstract Derivatives of 7H-1,3,4-thiadiazolo-[3,2-a]-pyrimidin-7-one-5-carboxylic acid having basic substituents in the 2-position, the alkyl esters and/or pharmaceutically useable salts of these compounds are new substances having immunstimulating properties, being especially valuable for antiinfectious therapy in mammals including man. The new products are prepared by reacting 2-amino-5-(basically substituted)-1,3,4-thiadiazoles with dialkylacetylenedicarboxylates and splitting the ester grouping in the obtained compound if desired and/or forming pharmaceutically acceptable salts.
Inventors
- 👤 Siegfried Herrling
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 16:48
CPC Classifications
C; C07; C07D; C07D285/00; C07D285/01; C07D285/02; C07D285/04; C07D285/12; C07D285/125; C07D285/135; C07D513/00; C07D513/02; C07D513/04
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
134 words
Heterocyclic compounds of the following general formula (I) ##STR24## wherein R represents hydrogen or an alkyl radical with 1 to 5 carbon atoms, R 1 and R 2 , which may be the same or different, represent alkyl radicals with 1 to 5 carbon atoms or together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring which may be substituted by one or more alkyl groups containing 1 to 3 carbon atoms which may also be interrupted by an oxygen or a sulfur atom or a R 3 -N< group, wherein R 3 represents an alkyl radical with 1 to 4 carbon atoms, a monocyclic aryl radical or an aralkyl radical with 1 or 2 carbon atoms in the alkylene group and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
134 words
Heterocyclic compounds of the following general formula (I) ##STR24## wherein R represents hydrogen or an alkyl radical with 1 to 5 carbon atoms, R 1 and R 2 , which may be the same or different, represent alkyl radicals with 1 to 5 carbon atoms or together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring which may be substituted by one or more alkyl groups containing 1 to 3 carbon atoms which may also be interrupted by an oxygen or a sulfur atom or a R 3 -N< group, wherein R 3 represents an alkyl radical with 1 to 4 carbon atoms, a monocyclic aryl radical or an aralkyl radical with 1 or 2 carbon atoms in the alkylene group and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
36 words
The heterocyclic compounds of claim 1, wherein said compounds are of the following general formula: ##STR25## wherein R is as defined in claim 1 and n is 4,5 or 6 and the pharmaceutically acceptable salts thereof.
Claim 4
Dependent Claim
30 words
The heterocyclic compounds of claim 1, wherein said compounds are of the following general formula: ##STR26## wherein R is as defined in claim 1, and the pharmaceutically acceptable salts thereof.
Claim 5
Dependent Claim
21 words
The heterocyclic compounds of claim 1, wherein said compound is ethyl 2-pyrrolidino-7H-1,3,4-thiadiazolo-[3,2-a]-pyrimidin-7-one-5-carboxylate and the pharmaceutically acceptable salts thereof with an acid.
Claim 6
Dependent Claim
30 words
The heterocyclic compounds of claim 1, wherein said compounds are of the following general formula: ##STR27## wherein R is as defined in claim 1 and the pharmaceutically acceptable salts thereof.
Claim 7
Dependent Claim
21 words
The heterocyclic compounds of claim 1, wherein said compound is ethyl 2-piperidino-7H-1,3,4-thiadiazolo-[3,2-a]-pyrimidin-7-one-5-carboxylate and the pharmaceutically acceptable salts thereof with an acid.
Claim 8
Dependent Claim
30 words
The heterocyclic compounds of claim 1, wherein said compounds are of the following general formula ##STR28## wherein R is as defined in claim 1, and the pharmaceutically acceptable salts thereof.
Claim 9
Dependent Claim
21 words
The heterocyclic compounds of claim 1 wherein said compound is ethyl 2-morpholino-7H-1,3,4-thiadiazolo-[3,2-a]-pyrimidin-7-one-5-carboxylate and the pharmaceutically acceptable salts thereof with an acid.
References Cited (Backward Citations)
DE2712932A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-07-27 | 1985-01-26 | 1985-07-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-07-27 | 1989-01-26 | 1989-07-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-07-27 | 1993-01-26 | 1993-07-28 | $7700.00 | Window Closed / Lapsed |